Non-small-cell Lung Cancer
Conditions
Keywords
epidermal growth factor receptor, EGFR mutation, Tyrosine kinase inhibitor, gefitinib, neo-adjuvant therapy
Brief summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1001. This is an open-label, single-arm, phase II interventional clinical trial. The investigators hypothesize that the application of EGFR-TKI, like gefitinib will be efficient and safe in a neo-adjuvant setting. 42 resectable stage II-IIIa NSCLC patients with EGFR activating (19/21) mutations will be eligible to be enrolled. EGFR mutation will be prospectively tested in all the participants' biopsy samples and confirmed in surgical resected samples. Eligible patients will be given gefitinib 250mg for 42days followed with surgical resection of tumor. Efficacy of preoperative gefitinib is based on radiographic (CT response/ORR), pathologic (pathologic response), surgical (complete resection) evaluations, and safety is based on adverse effect evaluations.
Interventions
DRUGGefitinib
Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Provision of informed consent 2. Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation. 3. Clinically or pathologically confirmed stage II-IIIA 4. Tolerable to complete resection of lung cancer 5. Male or female aged 18 years and over 6. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications 7. ECOG performance status 0-1. 8. Life expectancy ≥12 weeks. 9. Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level). 10. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 x upper limit of normal (ULN). 11. Adequate renal function: Serum creatinine ≤ 1.5 x upper limit of normal (ULN), and creatinine clearance≥ 60 ml/min. 12. Measurable disease according to the preset criteria .
Exclusion criteria
1. Known severe hypersensitivity to gefitinib or any of the excipients of this product 2. Any serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study 3. Interstitial lung disease(ILD) or pulmonary fibrosis; impaired pulmonary function (e.g. FEV1 \<40% predicted value, artery blood gas PaO2\<60mmHg) 4. Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab). 5. Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer therapy (e.g. monoclonal antibody therapy) for lung cancer. 6. Previous or current malignancies of other histologies within the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free survival of 5 years; cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix. 7. Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within six months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). 8. Eye inflammation or eye infection not fully treated or predisposing factor of this. 9. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the subject at high risk for treatment-related complications. 10. Patient who has serious active infection 11. Patients who harbouring exon 20 T790M mutation. 12. Pregnancy or breast feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) | at day 42 of gefitinib treatment |
Secondary
| Measure | Time frame |
|---|---|
| Complete resection rate | Complete resection rate is depended on the pathology dignosis after surgery, an expected average of 8 weeks from enrollment. |
| Number of participants with adverse events | During the neoadjuvant and perioperative period, an expected average of 10 weeks from enrollment |
| Pathologic response rate | Pathologic response rate is depended on the pathology dignosis after surgery, an expected average of 8 weeks from enrollment. |
| Disease free survival (DFS) | Participants after surgery will receive long-term follow-up for up to 5 years |
| Overall survival (OS) | Participants after surgery will receive long-term follow-up for up to 5 years |
| Quality of life (QoL) | During the neoadjuvant period, an expected average of 6 weeks from enrollment |
Countries
China
Outcome results
None listed